Highlights,Merck gains two new EU approvals for KEYTRUDA in gynecologic cancers.,Approvals cover treatments for advanced ...

Trodelvy shows effectiveness in real-world breast cancer treatment, even after receiving Enhertu therapy. For patients with ...

After the disastrous performance of 2022, the market has recovered better than expected and is on a growth trajectory.

Merck (MRK) announced that the European Commission (EC) has approved two new indications for Keytruda, Merck’s anti-PD-1 therapy, in ...

The European Commission (EC) has approved two new indications for Keytruda (pembrolizumab), Merck & Co’s anti-PD-1 therapy, ...

Three absurdly cheap dividend stocks that are trading at modest multiples of their expected earnings today are Merck (NYSE: ...

Merck's Keytruda now approved by European Commission for new gynecologic cancer indications, expanding its reach in the EU.

In NRG-GY018/KEYNOTE-868, KEYTRUDA in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, ...

The financial implications of breast cancer treatment are significant, with patients facing costs ranging from R10 000 to R2 ...

To say this has been a big year for Summit Therapeutics (NASDAQ: SMMT) would be a huge understatement. The stock has risen ...

Modifi Biosciences announced that it has been acquired by global pharmaceutical giant Merck, with a $30 million down payment.